U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C6H5O7.3Zn
Molecular Weight 574.426
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC CITRATE

SMILES

[Zn++].[Zn++].[Zn++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

InChI

InChIKey=WGIWBXUNRXCYRA-UHFFFAOYSA-H
InChI=1S/2C6H8O7.3Zn/c2*7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h2*13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;;3*+2/p-6

HIDE SMILES / InChI
Molecular Formula C6H5O7
Molecular Weight 189.0997
Charge -3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: http://www.npi.gov.au/resource/zinc-and-compounds | https://www.ncbi.nlm.nih.gov/pubmed/27546855 | https://www.ncbi.nlm.nih.gov/pubmed/6353570http://www.chemistrylearner.com/zinc-hydroxide.html | http://www.lookchem.com/Zinc-hydroxide/http://www.azom.com/article.aspx?ArticleID=8415 | https://www.accessdata.fda.gov/scripts/fdcc/?set=IndirectAdditives&id=ZINCSULFIDE | http://www.imse.iastate.edu/files/2014/03/Jianqiang_Li_Master_Thesis.pdf | https://www.ncbi.nlm.nih.gov/pubmed/24477783http://www.t3db.ca/toxins/T3D0733https://www.google.com/patents/US3130034https://www.drugs.com/mtm/zinc-oxide-topical.htmlhttp://www.hmdb.ca/metabolites/HMDB01303http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125327s020lbl.pdfhttps://www.ewg.org/skindeep/ingredient/724913/ZINC_CARBONATE/# | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.80 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=347.10 | https://www.ncbi.nlm.nih.gov/pubmed/10378806 | https://www.ncbi.nlm.nih.gov/pubmed/17633459
Curator's Comment: description was created based on several sources, including http://www.healio.com/news/print/hemonc-today/%7Bfc05fb30-107a-4753-b673-bd0e9b19881d%7D/glucarpidase-in-the-treatment-of-methotrexate-induced-nephrotoxicity

Zinc monocarbonate (Zinc Carbonate) is an inorganic salt. In the United States, Zinc Carbonate may be used as an active ingredient in OTC drug products. When used as an active drug ingredient, the established name is Zinc Carbonate. Zinc monocarbonate is generally recognized as safe by FDA. It is used as skin protectant active ingredient. Zinc carbonate was found to retard the degradation of some poly(lactide-co-glycolide) (PLG) microspheres in vivo and in vitro. Adding Zinc Carbonate is essential during the preparation of PLGA microspheres. It can remarkably improve the stability of drugs in the acid microenvironment inside PLGA microspheres.

CNS Activity

CNS Active
3913
Curator's Comment: Spatial memory deficits in a mouse model of late-onset Alzheimer's disease were caused by Zinc Carbonate supplementation. Long-term dietary administration of zinc ( Zinc Carbonate) can lead to impairments in cognitive function in rats. Microprobe synchrotron X-ray fluorescence (microSXRF) confirmed that brain zinc levels were increased by adding Zinc Carbonate to the drinking water.

Originator

Smithson, R.
38
Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Activator
1430
Activator
1430
Hydrolytic Enzyme
38
ultraviolet B-induced damage
38
Target ID: ultraviolet B-induced damage
Interacts
323
Activator
1430
Zinc transporter ZIP1
38
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Zinc transporter ZIP2
38
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Binding Agent
1064
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Basic research
Unknown

Approved Use

Unknown
Primary
Approved
8429
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

1955
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Primary
Basic research
Unknown

Approved Use

Unknown
Secondary
Approved
8429
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

2012
Primary
Approved
8429
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

2006
Primary
Approved
8429
ZINC OXIDE

Approved Use

Unknown
Primary
Approved
8429
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
Phase III
656
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
Phase III
656
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
PubMed

PubMed

TitleDatePubMed
A medicated polycarboxylate cement to prevent complications in composite resin therapy.
1990 Jan
Zinc inhibition of renin and the protease from human immunodeficiency virus type 1.
1991 Sep 10
Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds.
1994 Dec
Iron chelators as therapeutic agents against Pneumocystis carinii.
1994 May
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.
1995 Nov 13
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.
1997 Feb
Thujaplicin-copper chelates inhibit replication of human influenza viruses.
1998 Aug
Bioavailability, biodistribution, and toxicity of BioZn-AAS(1): a new zinc source. comparative studies in rats.
2000 Sep
Characterization and inhibition of SARS-coronavirus main protease.
2006
Zinc nutritional status of morbidly obese patients before and after Roux-en-Y gastric bypass: a preliminary report.
2006 Apr
Effect of end-stage renal disease and diabetes on zinc and copper status.
2006 Jul
Elevated cortical zinc in Alzheimer disease.
2006 Jul 11
The effect of Ramadan on maternal nutrition and composition of breast milk.
2006 Jun
Seminal plasma zinc concentration and alpha-glucosidase activity with respect to semen quality.
2006 May
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.
2006 May
Zinc homeostasis in aging: two elusive faces of the same "metal".
2006 Summer
Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles.
2007 May
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing.
2010 Dec
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.
2010 Feb
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells.
2010 Jan 12
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.
2010 Jul
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway.
2010 Oct
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways.
2011 Dec
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.
2011 Jul
Titanium oxide shell coatings decrease the cytotoxicity of ZnO nanoparticles.
2011 Mar 21
Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study.
2011 Sep
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity.
2012 Feb
Aerosolized ZnO nanoparticles induce toxicity in alveolar type II epithelial cells at the air-liquid interface.
2012 Feb
Association of zinc ion release and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung.
2012 Jun 25
Zinc oxide nanoparticles-induced intercellular adhesion molecule 1 expression requires Rac1/Cdc42, mixed lineage kinase 3, and c-Jun N-terminal kinase activation in endothelial cells.
2012 Mar
Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts.
2012 May 5
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.
2013 Dec
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013 Jan
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.
2013 Jul 31
Reactive oxygen species-induced cytotoxic effects of zinc oxide nanoparticles in rat retinal ganglion cells.
2013 Mar
Inorganic salts in atmospheric particulate matter: Raman spectroscopy as an analytical tool.
2013 Nov
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation.
2013 Sep
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.
2014 Apr
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.
2014 Jan
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.
2014 Jul 1
ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice.
2014 Nov 4
Ultrasonic assisted removal of sunset yellow from aqueous solution by zinc hydroxide nanoparticle loaded activated carbon: Optimized experimental design.
2015
Endoplasmic reticulum stress and oxidative stress are involved in ZnO nanoparticle-induced hepatotoxicity.
2015 Apr 2
Simultaneous sulfate and zinc removal from acid wastewater using an acidophilic and autotrophic biocathode.
2016 Mar 5
Spectroscopic probe to contribution of physicochemical transformations in the toxicity of aged ZnO NPs to Chlorella vulgaris: new insight into the variation of toxicity of ZnO NPs under aging process.
2016 Oct
Risk Assessment Study of Fluoride Salts: Probability-Impact Matrix of Renal and Hepatic Toxicity Markers.
2016 Sep
Mycobacterial carbonic anhydrase inhibition with phenolic acids and esters: kinetic and computational investigations.
2016 Sep 21
Intense 2.7μm emission in Er(3+) doped zinc fluoride glass.
2017 May 15
Patents

Patents

04005147
106
04090844
38
04134847
38
04292237
38
04376079
39
04377675
40
04404196
40
04565693
38
04670586
38
04740363
38
04743435
42
04904401
38
04950702
42
05064815
38
05149745
38
05442047
38
05539121
38
05646324
38
05773011
38
05911978
38
06140331
38
06303833
38
06706904
38
07375243
38
07585885
44
07799339
38
07959530
39
08258190
38
20060128799
38
20060270867
38
20070213331
40
20070249787
39
20080274173
38
20090092554
38
20100048844
38
20100117110
38
20100324259
38
7632959
38
CN105567322
38
EP0119068A1
38
US1767667
38
US20070265374
38
US2522537
38
US2537262
38
US3248354
38
US3453072
38
US3790469
38
US6853140
38

Sample Use Guides

In Vivo Use Guide
Rats: The dosage of zinc fluoride tetrahydrate (ZnF2 •4H2O) was adjusted to contain 2.1 mg (low-dose group, LG), 4.3 mg (mid-dose group, MG), and 5.4 mg fluoride per 200 g rat body weight (high-dose group, HG) corresponding to 5, 10, and 12.5 % of LD50 values for NaF.
Route of Administration: Oral
In Vitro Use Guide
Prepared ground human enamel specimens were immersed in zinc fluoride solutions containing 250 and 750 ppm F- at pH 6 and 4 for 4 min.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:02:49 GMT 2023
Edited
by admin
on Fri Dec 15 15:02:49 GMT 2023
Record UNII
K72I3DEX9B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINC CITRATE
INCI   MART.   MI   WHO-DD  
INCI  
Official Name English
CITRATED ZINC [VANDF]
Common Name English
2-HYDROXY-1,2,3-PROPANETRICARBOXYLIC ACID ZINC SALT
Common Name English
ZINC CITRATE [INCI]
Common Name English
ZINC CITRATE [MART.]
Common Name English
ZINC CITRATE [MI]
Common Name English
Zinc citrate [WHO-DD]
Common Name English
CITRATED ZINC
VANDF  
Common Name English
Classification Tree Code System Code
DSLD 137 (Number of products:9660)
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID90889427
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
ECHA (EC/EINECS)
208-901-2
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
DRUG BANK
DB11154
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
EVMPD
SUB15754MIG
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
NCI_THESAURUS
C84247
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
DAILYMED
K72I3DEX9B
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
NCI_THESAURUS
C1505
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
CONCEPT Dietary Supplement
RXCUI
236911
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY RxNorm
MERCK INDEX
m11603
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY Merck Index
SMS_ID
100000089512
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
PUBCHEM
11023
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
FDA UNII
K72I3DEX9B
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
CAS
546-46-3
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
Related Record Type Details
Structure of ZINC CITRATE DIHYDRATE
SOLVATE->ANHYDROUS
Structure of ZINC CATION
PARENT -> SALT/SOLVATE
Structure of ZINC CITRATE TRIHYDRATE
SOLVATE->ANHYDROUS
Structure of ANHYDROUS CITRIC ACID
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of ZINC CATION
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966